Neumora Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Neumora Therapeutics

09/05/2025 21:48

Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to show no change in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

​LSEG's mean analyst estimate for Neumora Therapeutics Inc is for a loss of 37 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.4% in the last three months. ​

Wall Street's median 12-month price target for Neumora Therapeutics Inc is $4.00​, above​ its last closing price of $0.64. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.46
-0.45
-0.37
Beat
17.1
Sep. 30 2024
-0.38
-0.39
-0.45
Missed
-15.4
Jun. 30 2024
-0.38
-0.37
-0.37
Met
0.4​
Mar. 31 2024
-0.34
-0.34
-0.34
Met
0.6
​​Dec. 31 2023
-0.73
-0.55
-0.71
Missed
-29.1
Sep. 30 2023
-0.36
-0.36
-1.14
Missed
-214.5​

This summary was machine generated May 9 at 20:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)